Q-omics provides the consensus-scored ZCCHC7 profile across patient tissues and cancer cell-line models. ZCCHC7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZCCHC7 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ZCCHC7 RNA expression shows 20,502 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where ZCCHC7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZCCHC7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZCCHC7 survival associations across molecular data types. ZCCHC7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZCCHC7 RNA expression–survival associations across cancer types. High ZCCHC7 expression shows unfavorable associations in KIRP, ACC, LIHC and KICH, but favorable associations in KIRC and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ZCCHC7 RNA expression.
This table summarizes ZCCHC7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZCCHC7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZCCHC7 shows lower tumor expression in THCA and higher tumor expression in KIRC, COAD, LIHC, HNSC and KIRP. The KIRC box plot shows higher ZCCHC7 RNA expression in tumor versus normal tissue (log2 FC = +0.531, t-test p < 0.001).
This table shows molecular features associated with ZCCHC7 in patient tissues and cancer cell lines. In patient samples, ZCCHC7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZCCHC7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
